NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Pain Relief Technology
NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No.
9,474,898. The patent covers key technology that enables safe delivery of Quell® therapy for chronic pain while the user
is sleeping. Over 80% of chronic pain sufferers report low quality sleep, which then further exacerbates pain. Quell is the only
high intensity transcutaneous electrical nerve stimulator cleared by the FDA for use while sleeping.
The claims cover a novel approach to using skin-electrode impedance measurements to continually monitor the Quell electrode
array contact area. If the area drops to a critical level due to unintended electrode peeling, the device automatically shuts off
electrical stimulation thereby providing a safety mechanism while the user is sleeping and unaware.
This patent further establishes and differentiates the leading technology and clinical benefits of Quell Wearable Pain Relief
Technology™.
About Quell
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be
worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic
pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can
start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that
provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive
leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best
Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets
DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for
restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from
the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027005194/en/